Psychiatric Pharmacogenomics

This book is designed with the clinician in mind. The book primarily covers the 14 genes relevant to psychiatric drug-gene interactions. Specific clinical examples and cases are used to underscore the specific indications for ordering pharmacogenomic tests and the clinical utility of the results that includes relating the results back to medication therapy. The clinical cases are unique to other books as they provide the potential laboratory report provided when a test is completed. Only the genes relevant to psychotropic medications are reviewed.

Type Book
CME Available No
Cost $42.22

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.


  • Basic Genetic Concepts
    • B3:   To identify drug and disease associated genetic variations that facilitate development of prevention, diagnostic and treatment strategies and appreciate there are differences in testing methodologies and are aware of the need to explore these differences these differences in drug literature evaluation
    • B4:   To use family history (minimum of three generations) in assessing predisposition to disease and selection of drug treatment
  • Ethical, Legal and Social Implications (ELSI)
    • E1:   To understand the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
    • E4:   To appreciate the cost, cost-effectiveness, and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation, for patients and populations
  • Genetics and Disease
    • G1:   To understand the role of genetic factors in maintaining health and preventing disease
    • G2:   To assess the difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
    • G3:   To appreciate that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g. the Apo E4 polymorphism)